Senator Josh Hawley just introduced legislation that would pull FDA approval from the abortion pill mifepristone entirely, marking the most aggressive congressional push yet to dismantle the Biden administration’s reckless expansion of mail-order chemical abortions.
Story Highlights
- Hawley’s Safeguarding Women from Chemical Abortion Act would revoke mifepristone’s FDA approval and classify its distribution for abortion as a federal crime
- The bill allows women harmed by the drug to sue manufacturers like Danco Laboratories, targeting billions in abortion industry profits
- Research shows mifepristone complications occur 22 times more often than FDA labels acknowledge, enabled by Biden-era deregulation
- The legislation arrives as President Trump’s FDA Commissioner conducts a parallel safety review of the dangerous drug
Hawley Targets Biden’s Reckless Abortion Pill Deregulation
Senator Josh Hawley introduced the Safeguarding Women from Chemical Abortion Act, directly confronting the Biden administration’s dismantling of safety protocols around mifepristone. The Missouri Republican’s legislation withdraws FDA approval for using the drug in abortions, criminalizes its distribution for pregnancy termination, and empowers harmed women to pursue legal action against manufacturers. This represents a significant escalation from Hawley’s 2025 bill that merely sought tighter safeguards. The new approach cuts straight to the core problem: a drug approved under strict conditions in 2000 was systematically deregulated by leftist bureaucrats who prioritized abortion industry profits over women’s health.
Chemical Abortion Now Dominates Despite Safety Concerns
Mifepristone accounted for 63 percent of all abortions in 2023, totaling over one million procedures according to Guttmacher Institute data. Biden administration changes between 2021 and 2023 eliminated in-person dispensing requirements, allowing telehealth consultations and mail delivery that pro-life organizations estimate facilitate 500 abortions daily. Research from the Ethics and Public Policy Center reveals complications occur 22 times more frequently than FDA labeling indicates, yet federal regulators turned a blind eye. This explosion in mail-order chemical abortions happened while safety standards collapsed, leaving women vulnerable to severe bleeding, incomplete abortions, and emergency interventions without proper medical supervision nearby.
Manufacturers Face Accountability Under New Framework
Representative Diana Harshbarger, a Tennessee Republican and pharmacist, is introducing companion legislation in the House that directly targets abortion pill manufacturers’ immunity. Danco Laboratories and similar companies have profited enormously from loosened regulations while real-world harm escalated beyond what their labels acknowledge. Harshbarger emphasized that safety and transparency must override political agendas, a principle abandoned under Biden’s FDA leadership. The bill’s liability provisions represent common-sense accountability: if pharmaceutical companies produce drugs causing demonstrable harm under unsafe distribution models, injured patients deserve legal recourse. This stands in stark contrast to the previous administration’s cozy relationship with abortion providers who prioritized convenience over patient welfare.
Trump Administration Alignment Strengthens Reform Prospects
Hawley’s legislative push coincides with FDA Commissioner Marty Makary’s ongoing safety review of mifepristone under President Trump’s administration, creating dual pathways for addressing the drug’s dangers. Hawley previously urged Makary to restore pre-Biden safeguards through correspondence highlighting the regulatory failures. Pro-life organizations including Concerned Women for America Legislative Action Committee commended the bill as a necessary confrontation with chemical abortion’s documented risks. The Supreme Court dismissed a 2024 legal challenge on procedural standing grounds without reviewing the drug’s safety merits, leaving the door open for congressional action. This coordinated approach between legislative and executive branches reflects the administration’s commitment to reversing Biden-era policies that sacrificed women’s safety for ideological extremism.
Bill Challenges Abortion Industry’s Profit-Driven Model
The legislation exposes the uncomfortable reality that abortion providers and drug manufacturers constructed a billion-dollar system built on eliminating safeguards that protected vulnerable women. Mail-order distribution removed physician oversight, converted pharmacies into abortion facilitators, and isolated women facing complications in rural areas without immediate medical assistance. Hawley’s March 10 press conference featured testimonies from women harmed by mifepristone alongside pro-life leaders who documented the human cost of regulatory capture. If enacted, the ban would disrupt approximately 63 percent of current abortion procedures and force a return to surgical methods with proper medical supervision. The economic implications extend beyond manufacturers to the broader telehealth abortion infrastructure that flourished under Biden, demonstrating how radical deregulation served corporate interests while endangering women under the guise of expanded access.
Sources:
Hawley introduces bill to strip FDA approval from ‘inherently dangerous’ abortion pill
Senator introduces bill to ban Obamacare-funded abortions
CWALAC Commends Sen. Hawley on Bill Confronting Abortion Pill’s Dangers
Hawley unveils bill to ban abortion pill, strip FDA approval
Hawley introduces bill to revoke FDA approval of abortion pill
